S hares of Cocrystal Pharma (NASDAQ:COCP) plunged 40% Tuesday after the company said it plans to extend a Phase 2a challenge study for its influenza drug candidate CC-42344 due to an unexpectedly ...

Overview: Cocrystal Pharma, Inc. is a biotechnology company dedicated to discovering and developing antiviral therapeutic treatments for serious and chronic viral diseases, with a market cap of $ ...

Cocrystal Pharma (NASDAQ:COCP) just reported results for the fourth quarter of 2023. Cocrystal Pharma reported earnings per share of -44 cents. This was above the analyst estimate for EPS of -60 ...

Cocrystal Pharma, Inc. (NASDAQ:COCP – Get Free Report) was the recipient of a significant decline in short interest in ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...